Emedastinum [INN-Latin] en es it fr

Emedastinum [INN-Latin] Brand names, Emedastinum [INN-Latin] Analogs

Emedastinum [INN-Latin] Brand Names Mixture

  • No information avaliable

Emedastinum [INN-Latin] Chemical_Formula


Emedastinum [INN-Latin] RX_link


Emedastinum [INN-Latin] fda sheet

Emedastinum_[INN-Latin] FDA

Emedastinum [INN-Latin] msds (material safety sheet)

Emedastinum [INN-Latin] Synthesis Reference

No information avaliable

Emedastinum [INN-Latin] Molecular Weight

393.436 g/mol

Emedastinum [INN-Latin] Melting Point

No information avaliable

Emedastinum [INN-Latin] H2O Solubility

Very slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)

Emedastinum [INN-Latin] State


Emedastinum [INN-Latin] LogP


Emedastinum [INN-Latin] Dosage Forms

Tablet (27.3 mg, 109.3 mg or 163.9 mg)

Emedastinum [INN-Latin] Indication

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Emedastinum [INN-Latin] Pharmacology

Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor.

Emedastinum [INN-Latin] Absorption

Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%.

Emedastinum [INN-Latin] side effects and Toxicity

Symptoms of overdose include diarrhea, rash, and liver transaminase elevation.

Emedastinum [INN-Latin] Patient Information

Emedastinum [INN-Latin] Organisms Affected

Humans and other mammals